Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD: a randomised controlled trial.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
05 2023
Historique:
received: 11 10 2021
accepted: 04 03 2022
medline: 17 4 2023
pubmed: 23 4 2022
entrez: 22 4 2022
Statut: ppublish

Résumé

Evidence suggests that patients with COPD struggle to maintain improved physical activity (PA) after completing pulmonary rehabilitation (PR). Smartphone applications (apps) providing a comprehensive training programme have conferred healthy benefits. This study was conducted to determine whether regular usage of an app maintains PA following PR. Patients with stage II-IV COPD were enrolled in a 6-month trial following PR. After the screening period, participants were randomised into the Kaia COPD app group (intervention group (IG)) or the control group (CG). The primary outcome was PA (daily steps), measured using an activity tracker. Secondary outcomes included the COPD Assessment Test (CAT), the Chronic Respiratory Disease Questionnaire (CRQ) and the 1 min Sit-to-Stand Test (STST). Sixty participants completed the study. The median steps from baseline to 6 months were significantly different between the groups, in favour of the IG (-105.3, IQR -1970.1 to 2105.8, vs CG -1173.0, IQR -3813.1 to -93.8; p=0.007). CAT was significantly decreased in the IG (15.1±8.6 vs 19.7±6.4, p=0.02), whereas the CRQ subdomains for dyspnoea (4.5±1.7 vs 3.7±1.3, p=0.033) and fatigue (4.5±1.4 vs 3.5±1.3, p=0.028) improved significantly in the IG. The STST at 6 months was not significant. Sleep duration and sleep efficiency showed no significant differences between the two groups at any time. A comprehensive program by using the Kaia app following PR maintained PA and improved symptoms in patients with COPD at 6 months. The app might be an important accessory tool for enhanced COPD care. DRKS00017275.

Sections du résumé

BACKGROUND
Evidence suggests that patients with COPD struggle to maintain improved physical activity (PA) after completing pulmonary rehabilitation (PR). Smartphone applications (apps) providing a comprehensive training programme have conferred healthy benefits. This study was conducted to determine whether regular usage of an app maintains PA following PR.
METHODS
Patients with stage II-IV COPD were enrolled in a 6-month trial following PR. After the screening period, participants were randomised into the Kaia COPD app group (intervention group (IG)) or the control group (CG). The primary outcome was PA (daily steps), measured using an activity tracker. Secondary outcomes included the COPD Assessment Test (CAT), the Chronic Respiratory Disease Questionnaire (CRQ) and the 1 min Sit-to-Stand Test (STST).
RESULTS
Sixty participants completed the study. The median steps from baseline to 6 months were significantly different between the groups, in favour of the IG (-105.3, IQR -1970.1 to 2105.8, vs CG -1173.0, IQR -3813.1 to -93.8; p=0.007). CAT was significantly decreased in the IG (15.1±8.6 vs 19.7±6.4, p=0.02), whereas the CRQ subdomains for dyspnoea (4.5±1.7 vs 3.7±1.3, p=0.033) and fatigue (4.5±1.4 vs 3.5±1.3, p=0.028) improved significantly in the IG. The STST at 6 months was not significant. Sleep duration and sleep efficiency showed no significant differences between the two groups at any time.
CONCLUSIONS
A comprehensive program by using the Kaia app following PR maintained PA and improved symptoms in patients with COPD at 6 months. The app might be an important accessory tool for enhanced COPD care.
TRIAL REGISTRATION NUMBER
DRKS00017275.

Identifiants

pubmed: 35450945
pii: thoraxjnl-2021-218338
doi: 10.1136/thoraxjnl-2021-218338
pmc: PMC10176348
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

442-450

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Respirology. 2019 Sep;24(9):909-915
pubmed: 30891887
Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793
pubmed: 25705944
Chest. 2011 Aug;140(2):331-342
pubmed: 21273294
NPJ Digit Med. 2019 May 3;2:34
pubmed: 31304380
Eur Respir J. 2016 Oct;48(4):1019-1029
pubmed: 27587557
Respir Res. 2017 Jun 2;18(1):112
pubmed: 28578705
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
Thorax. 2020 May;75(5):413-421
pubmed: 32229541
Chest. 2021 Dec;160(6):2080-2100
pubmed: 34217679
J Clin Med. 2020 Jul 31;9(8):
pubmed: 32751825
Cochrane Database Syst Rev. 2021 Aug 17;8:CD013569
pubmed: 34404111
BMJ Open. 2017 Jul 17;7(7):e014580
pubmed: 28716786
Eur Respir J. 2009 Feb;33(2):262-72
pubmed: 19010994
Respir Care. 2015 Apr;60(4):540-8
pubmed: 25516993
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33263052
Int J Chron Obstruct Pulmon Dis. 2018 Nov 23;13:3831-3836
pubmed: 30538444
Chron Respir Dis. 2012 Feb;9(1):17-26
pubmed: 22194629
Int J Chron Obstruct Pulmon Dis. 2016 Dec 08;11:3121-3136
pubmed: 27994451
Cochrane Database Syst Rev. 2016 Dec 08;12:CD005305
pubmed: 27930803
J Med Internet Res. 2017 Dec 18;19(12):e422
pubmed: 29254906
Eur Respir J. 2014 Dec;44(6):1521-37
pubmed: 25359358
PLoS One. 2016 Jun 15;11(6):e0157229
pubmed: 27305105
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Eur Respir J. 2018 Nov 22;52(5):
pubmed: 30409819
Dtsch Med Wochenschr. 2017 Jan;142(2):e10-e19
pubmed: 28114711
Life (Basel). 2021 Nov 15;11(11):
pubmed: 34833112
Chest. 2013 Oct;144(4):1091-1093
pubmed: 24081336
JMIR Mhealth Uhealth. 2020 Jun 3;8(6):e16203
pubmed: 32490838
Chron Respir Dis. 2019 Jan-Dec;16:1479973118816424
pubmed: 30789017
NPJ Digit Med. 2020 Oct 30;3:145
pubmed: 33145441
Nat Biotechnol. 2016 Mar;34(3):239-46
pubmed: 26963544
J Clin Med. 2019 Mar 11;8(3):
pubmed: 30862102
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64
pubmed: 24127811
Thorax. 1987 Oct;42(10):773-8
pubmed: 3321537
JMIR Mhealth Uhealth. 2021 Jun 11;9(6):e21728
pubmed: 34114960
Trials. 2020 Jul 11;21(1):636
pubmed: 32653025
Health Qual Life Outcomes. 2003 Aug 01;1:29
pubmed: 12914662

Auteurs

Marc Spielmanns (M)

Pulmonary Medicine, Zuercher RehaZentren Klinik Wald, Wald, Switzerland spielmanns@me.com.
Faculty of Health, Department for Pulmonary Medicine, University Witten Herdecke, Witten, Germany.

Rainer Gloeckl (R)

Pulmonary Rehabilitation, Philipps-Universität Marburg, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany.

Inga Jarosch (I)

Pulmonary Rehabilitation, Philipps-Universität Marburg, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany.

Daniela Leitl (D)

Pulmonary Rehabilitation, Philipps-Universität Marburg, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany.

Tessa Schneeberger (T)

Pulmonary Rehabilitation, Philipps-Universität Marburg, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany.

Tobias Boeselt (T)

Pulmonary Medicine, Philipps University Marburg Faculty of Medicine, Marburg, Germany.

Stephan Huber (S)

Kaia Health GmbH, Munich, Bavaria, Germany.

Pawandeep Kaur-Bollinger (P)

Kaia Health GmbH, Munich, Bavaria, Germany.

Bernhard Ulm (B)

Unabhaengige Statistische Beratungen Bernhard Ulm, Munich, Bavaria, Germany.

Claudia Mueller (C)

Kaia Health GmbH, Munich, Bavaria, Germany.

Jonas Bjoerklund (J)

Kaia Health GmbH, Munich, Bavaria, Germany.

Sabine Spielmanns (S)

Pulmonary Medicine, Zuercher RehaZentren Klinik Wald, Wald, Switzerland.

Wolfram Windisch (W)

Faculty of Health, Department for Pulmonary Medicine, University Witten Herdecke, Witten, Germany.
Department of Pneumology, Cologne Merheim Hospital, Kliniken der Stadt Koeln, Koeln, Germany.

Anna-Maria Pekacka-Egli (AM)

Pulmonary Medicine, Zuercher RehaZentren Klinik Wald, Wald, Switzerland.

Andreas Rembert Koczulla (AR)

Pulmonary Rehabilitation, Philipps-Universität Marburg, Marburg, Germany.
Institute for Pulmonary Rehabilitation Research, Schoen Klinik Berchtesgadener Land, Schoenau am Koenigssee, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH